This database provides a catalog of the therapeutics currently or previously tested as treatment for Alzheimer's disease and related disorders, focusing on those that have progressed to Phase 2 or beyond in U.S. clinical trials. We strive to keep this database up-to-date and welcome you to contact us at


Back to the Top
Search Therapeutics

AD Target / Therapy Types

The two tables below organize the therapeutics within this database by therapy type and proposed target type. The number of therapeutics within each category is indicated according to the highest phase each therapeutic has achieved in U.S. clinical trials. For example, if a given therapeutic is in both Phase 2 and Phase 3 trials, it is included in the Phase 3 total.


Recent Comments

  1. Clemens Scherzer on CST-103
  2. Mary Newport on Nasal Insulin
  3. William Frey II on Nasal Insulin
  4. Lindsay Burns on Simufilam

Further Reading


  1. Moving Alzheimer’s Diagnosis to Primary Care Could Ease Bottlenecks
  2. Adieu to Aduhelm: Biogen Stops Marketing Antibody
  3. Brain of Woman Who Died on Leqembi Shows Worst-Case Scenario
  4. 2023—A Bumper Year for the Treatment and Science of Alzheimer's


  1. Suzanne Hendrix on Constructing Composites for Trials in Early Alzheimer’s
  2. Computational Modeling—Will it Rescue AD Clinical Trials?
  3. Resolving Controversies on the Path to AD Therapeutics
  4. Treating Before Symptoms—ADCS Invites Ideas for Clinical Trials in Very Early AD

Other Resources

ADataViewer is an interactive platform that facilitates the exploration of 20 cohort datasets with respect to longitudinal follow-up, demographics, ethnoracial diversity, measured modalities, and statistical properties of individual variables.

ADDF ACCESS is a program to provide scientists in academia and small biotechnology companies with access to a virtual network of drug discovery experts and contract research organizations (CROs) that have experience developing therapies for neurodegenerative diseases.

Patient Resources